Investigating genetic similarities between primary colorectal tumors and their brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the molecular genetic profiles of primary colorectal cancer tumors and their corresponding brain metastases. By examining tumor samples from patients who have undergone neurosurgical resection, the study will assess the mutation status of key genes including KRAS, NRAS, BRAF, and HER2. The goal is to determine the concordance rate of these mutations between the primary tumors and brain metastases, which could provide insights into the biology of metastatic colorectal cancer. The research is based on a retrospective analysis of a limited number of patient samples collected over 26 years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Men and women over 18 years of age.
2. Histologically confirmed cancer of the colon or rectum.
3. Histologically confirmed metastatic lesion of the brain.
4. Neurosurgical resection for brain metastases of colorectal cancer.
5. Presence of paired tumor samples (both primary tumor and intracranial material).

Exclusion Criteria:

1. Missing one sample from a pair of tumor samples.
2. Low quality or lack of tumor material for molecular genetic research.

Where it's running

• Blokhin's Russian Cancer Research Center
  Moscow, Moscow, Russia Recruiting

Study contacts

• Study coordinator: David Halafyan, MD
• Email: daveupnow@gmail.com
• Phone: +7(930)928-00-72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases

  This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Scripps Health · La Jolla, California · NCT07550088

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

• Whole-body HER2 PET/CT to see how 89Zr-trastuzumab accumulates in HER2-positive or HER2-mutated advanced NSCLC

  This study tests whether 89Zr-trastuzumab PET/CT can show how much tracer builds up in tumors of adults with HER2-positive or HER2-mutated advanced NSCLC.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT07436858

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.